Aclaris Therapeutics is a biopharmaceutical company focused on identifying, developing and commercializing drugs to address the needs in aesthetic dermatology. Co.'s key product, ESKATA topical solution, is a formulation of high-concentration hydrogen peroxide topical solution approved by U.S. Food and Drug Administration as a prescription treatment for seborrheic keratosis, a non-malignant skin tumor. Co. is also developing A-101 45% Topical Solution as a prescription treatment for common warts, also known as verruca vulgaris. Co. in-licensed rights to certain inhibitors of the Janus kinase family of enzymes, for specified dermatological conditions, including alopecia areata, and vitiligo. We show 16 historical shares outstanding datapoints in our coverage of ACRS's shares outstanding history.
Understanding the changing numbers of ACRS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACRS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACRS by allowing them to research ACRS shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
